A 44-year-old woman was admitted to the neurosurgery department of our hospital on December 8, 2014, due to epilepsy, accompanied by headache and decreased muscle strength of both lower limbs for 1 month. Enhanced cranial MRI showed a solid lesion in the left frontal lobe. Intracranial tumor resection was performed on December 17, 2014. The pathological diagnosis was grade II astrocytoma. The prescription dose of head postoperative radiation was: PGTVtb64.4Gy/28fractions; PTVtb50.4Gy/28fractions; TMZ was concurrently administrated with postoperative radiotherapy. The dose of TMZ was 75 mg/m2 daily concurrent with radiotherapy, then 150 mg/m2 postirradiation on a 5-day schedule every 4 weeks. The patient was followed up regularly after radiotherapy. The brain MRI on March 9, 2018, showed irregular ring enhancement in the left frontal lobe, with a range of about 2.9 x 3.4 x 3.5 cm (Fig. 1 A-C). The patient underwent intracranial tumor resection on March 23, 2018, and postoperative pathology was glioblastoma (GBM), WHO grade IV. Immunohistochemistry results: vimentin (+++), glial fibrillary acidic protein (+++), isocitrate dehydrogenase (+++), Olig2 (+++), P53 (+80%), S-100 (+++), neuron-specific enolase (-), Syno (+), NeuN (-), NF (-), ChrA (-), epithelial membrane antigen (-), Ki-67 (+30%). She rejected gene mutation detection of the status of 1p/19q. The brain MRI re-examination on May 11, 2018 showed abnormal enhancement around the local operative area after resection of the left frontal lobe tumor, and there was residual tumor present (Fig. 2 A-C). After the reoperation of recurrence, the patient received conventionally fractionated stereotactic radiotherapy (CFRT) plus TMZ concurrent chemotherapy. The TMZ dose applied was 150 mg/m2 day 1 to day 7, every 2 weeks, concurrent with radiotherapy, then 150 mg/m2 postirradiation on a 7-day schedule every 2 weeks. Epilepsy did not appear again so far. Evaluation of cranial enhanced MRI (Fig. 3 A-C) after chemoradiotherapy showed complete remission of remaining intracranial lesions at the end of radiotherapy and 1 month after radiotherapy. Informed consent of the patient has been obtained.